Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.44 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27694206 | 0.92 | IGLV6-57 (0.50) | ACHEIGLV6-57NAAA | |
| SCHEMBL7051358 | 0.91 | GNAI3 (0.49) | ACHEGNAI3GNAO1GNAI1 | |
| SCHEMBL19064001 | 0.87 | SLC6A1 (0.40) | ACHEIGLV6-57 | |
| SCHEMBL19064114 | 0.85 | IGLV6-57 (0.39) | IGLV6-57 | |
| SCHEMBL19064129 | 0.84 | SLC6A1 (0.42) | ACHEIGLV6-57 | |
| SCHEMBL16145641 | 0.83 | ACHE (0.53) | ACHE | |
| SCHEMBL19064062 | 0.82 | MAPT (0.46) | IGLV6-57 | |
| SCHEMBL19064152 | 0.81 | CA12 (0.44) | ACHE | |
| SCHEMBL23063453 | 0.80 | SLC6A1 (0.47) | — | |
| SCHEMBL13387497 | 0.79 | ACHE (0.49) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3400228-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| US-8569484-B2 | Heterocyclic urea derivatives and methods of use thereof | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-20120122817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | UROD, UMPS, SLC14A1 | ACHE 325/4885IGLV6-57 2250/4885NAAA 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.